Research programme: adenosine A3 receptor agonists - Rocket
Alternative Names: Adenosine A3 receptor agonists - Rocket; INO-7997; PJ 997Latest Information Update: 09 Jan 2018
At a glance
- Originator Inotek Pharmaceuticals
- Class
- Mechanism of Action Adenosine A3 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Asthma; Inflammation
Most Recent Events
- 04 Jan 2018 Rocket Pharmaceuticals merged with Inotek Pharmaceuticals and the combined company was named Rocket Pharmaceuticals
- 13 Sep 2007 Discontinued - Preclinical for Asthma in USA (unspecified route)
- 13 Sep 2007 Discontinued - Preclinical for Inflammation in USA (unspecified route)